In the Brief Report titled “Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non–Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial,”1 published online August 30, 2018, there was an error in Figure 2. The text and the overall survival data were correct, but the Kaplan-Meier curves and median values were incorrect. This article was corrected online.
1.Gridelli
C, de Castro Carpeno
J, Dingemans
A-MC,
et al. Safety and efficacy of bevacizumab plus standard-of-care treatment beyond disease progression in patients with advanced non–small cell lung cancer: the AvaALL randomized clinical trial [published online August 30, 2018].
JAMA Oncol. doi:
10.1001/jamaoncol.2018.3486.
Google Scholar